Medical Device Company Moves from Kendall Square to Medford

| September 22, 2015 | Business News, Health and Wellness | No Comments

Seventh Sense Biosystems leases 9,000-square-foot office/lab with Cummings Properties

200 Boston Ave Medford

Seventh Sense Biosystems (7SBio) is relocating from Cambridge’s Kendall Square to Cummings Properties’ 200 Boston Avenue building in Medford. The firm, which develops blood collection and diagnostic platforms, has grown steadily, moving three times since its founding in 2008.

Cummings Properties leasing manager Derek Cook worked with Mark Winters of Cushman & Wakefield to find the ideal space for 7SBio. The privately held medical technology company will move this month into its new 9,000-square-foot suite, which is a combination of clean room, lab, and office space.

“It’s not at all unusual for businesses to migrate outside the city as they grow,” according to Cook. “The labs throughout our suburban portfolio provide a value that allows firms to save significantly on rent and dedicate more resources to research and development.”

7SBio is the fourth growing company to leave Cambridge for one of Cummings’ suburban locations during the past year. Its move follows relocations by Blue Stream Laboratories, CONTINUUS Pharmaceuticals, and Peritia.

“We were pleased to be able to satisfy Seventh Sense Biosystems’ immediate need for a clean room for manufacturing—something that is essential to its processes,” said Cook. “We also have the capacity in our 10 million-square-foot portfolio to allow the company to expand in the future.”

7SBio is best known for its proprietary Touch Activated Phlebotomy (TAPTM) technology platform, which draws blood in a virtually painless one-step process, reducing the discomfort and anxiety that often accompany blood based diagnostics, according to CEO Howard Weisman.

“The facility at 200 Boston is the right combination of quality laboratory and manufacturing space, value, and access to the entire metro area that we were looking for as we begin to commercialize our first products in 2016,” said Weisman.

The company announced in August that it has been granted a total of seven (7) patents in the U.S. and Europe with many more under review around the world.

– Submitted by Cummings Properties